Skip to content
OpenCapital
Get started

Nurix Therapeutics, Inc. NRIX Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss

Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
——

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$2B+40.1%

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio6×-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
Nurix Therapeutics, Inc. (NRIX) reported debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss of $536.44M in Q4 2025.